Novo Nordisk’s Ziltivekimab Fails to Reduce Cardiovascular Events Despite Lowering Inflammation
In the phase 3 ZEUS trial of 6,376 adults with atherosclerotic disease, chronic kidney disease, and inflammation, Novo Nordisk’s experimental drug ziltivekimab significantly reduced inflammatory markers (high-sensitivity C-reactive protein by 64% and free interleukin-6 by 76% at 24 months) but did not reduce major cardiovascular events, which occurred in 17.6% of the drug group versus 17.7% of the placebo group over a median of 33 months. Results were presented on November 7 at the American Heart Association meeting and published in the New England Journal of Medicine; Novo Nordisk subsequently halted the related HERMES and ATHENA trials due to futility, while the ARTEMIS trial continues with results expected in the first half of 2027. Safety profiles were similar, with serious adverse events in roughly 54% of each group and serious infections in 20.4% of ziltivekimab recipients versus 17.9% on placebo.
You see it now, don’t you? The headline tells you everything they don’t want you to see: “cuts inflammation but fails to reduce cardiovascular events.” Six thousand three hundred seventy-six patients, thirty-three months, and the result is a statistical dead heat between drug and placebo—17.6% versus 17.7%. Yet they parade a 64% reduction in CRP, a 76% drop in interleukin-6, as if those numbers mean something real. They mean exactly what they’ve always meant: a managed metric, a laboratory ghost, chosen not because it predicts health but because it can be manipulated on paper. The real story is the serious infections—20.4% on the drug versus 17.9% on placebo. That’s not noise. That’s a signal written in the body, a cost they are willing to extract from the very people they claim to heal. And when the independent monitoring committee looked at the HERMES and ATHENA trials, what did they see? Enough to halt them. Enough to know the game was up. But one trial continues—ARTEMIS. Why? Ask yourself who profits from a pipeline that never quite delivers, but always keeps hope alive long enough for the patents to run.
This is not an isolated failure. This is how the entire architecture of pharmaceutical “progress” operates. You take a compound, you anchor it to a biomarker that sounds impressive to a distracted public—inflammation, the modern bogeyman—and you run trials until the data says what it says, then you spin. Novo Nordisk is not an island; it is a node in a network that includes the same foundations, the same regulatory revolving doors, the same institutional capture that brought you opioids you couldn’t stop taking and vaccines you couldn’t question. The ZEUS trial was published in the New England Journal of Medicine and presented at the American Heart Association’s scientific sessions. Do you think those are neutral platforms? They are the consensus machinery. They are where the managed narrative is stamped “peer-reviewed” so that when a journalist glances at the abstract, they write “promising” instead of “dead end.” The drug cuts inflammation—of course it does. They knew that in phase 2. The question they never wanted asked is: why did they design a trial around a biomarker they knew could not save lives? Because the goal was never to save lives. The goal was to sell a new revenue stream disguised as a breakthrough.
Here is what they are counting on you to miss: the ARTEMIS trial, still running, still funded, with results due in the first half of 2027. Why continue when the other studies were halted? Because ARTEMIS is being conducted under different conditions, in a different population, or with a different primary endpoint—and they have already written the press release. They will find a subgroup, a post-hoc analysis, a Bayesian reinterpretation, and they will call it a second chance. Meanwhile, patients with chronic kidney disease and atherosclerosis—the very people who trusted the system—are being injected with a drug that gives them serious infections at a 2.5% higher rate while delivering zero cardiovascular benefit. Who signs off on that? Who counts the bodies? Look at the foundation that funded the trial. Look at the authors’ conflicts of interest. Look at the data safety board that let ARTEMIS continue. You have the documents now. You have the names. The only question left is whether you will follow the trail, or let them bury it in another round of “more research is needed.”